Advanced

A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists

Rizos, A.; Sauerbier, A.; Antonini, A.; Weintraub, D.; Martinez-Martin, P.; Kessel, B.; Henriksen, T.; Falup-Pecurariu, C.; Silverdale, M. and Durner, G., et al. (2016) In European Journal of Neurology 23(8). p.61-1255
Abstract

Background and purpose: Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical occurrence of impulse control behaviours on longer acting/transdermal DA therapy across age ranges are lacking. The aim of this study was to assess the occurrence of ICDs in PD patients across several European centres treated with short- or long-acting [ropinirole (ROP); pramipexole (PPX)] and transdermal [rotigotine skin patch (RTG)] DAs, based on clinical survey as part of routine clinical care. Methods: A survey based on medical records and clinical interviews of patients initiating or initiated on DA treatment (both short- and long-acting, and transdermal)... (More)

Background and purpose: Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical occurrence of impulse control behaviours on longer acting/transdermal DA therapy across age ranges are lacking. The aim of this study was to assess the occurrence of ICDs in PD patients across several European centres treated with short- or long-acting [ropinirole (ROP); pramipexole (PPX)] and transdermal [rotigotine skin patch (RTG)] DAs, based on clinical survey as part of routine clinical care. Methods: A survey based on medical records and clinical interviews of patients initiating or initiated on DA treatment (both short- and long-acting, and transdermal) across a broad range of disease stages and age groups was performed. Results: Four hundred and twenty-five cases were included [mean age 68.3 years (range 37-90), mean duration of disease 7.5 years (range 0-37)]. ICD frequencies (as assessed by clinical interview) were significantly lower with RTG (4.9%; P <0.05) compared with any other assessed DAs except for prolonged release PPX (PPX-PR). The rate of ICDs for PPX-PR (6.6%) was significantly lower than for immediate release PPX (PPX-IR) (19.0%; P <0.05). Discontinuation rates of DA therapy due to ICDs were low. Conclusion: Our data suggest a relatively low rate of ICDs with long-acting or transdermal DAs, however these preliminary observational data need to be confirmed with prospective studies controlling for possible confounding factors.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Dopamine agonists, Dopamine dysregulation syndrome, Impulse control behaviours/disorders, Parkinson's disease
in
European Journal of Neurology
volume
23
issue
8
pages
61 - 1255
publisher
Wiley-Blackwell
external identifiers
  • Scopus:84969922814
ISSN
1351-5101
DOI
10.1111/ene.13034
language
English
LU publication?
yes
id
40e099e3-4c96-4422-a8c4-3a6bff21bcfa
date added to LUP
2016-06-21 15:13:24
date last changed
2016-10-27 09:23:29
@misc{40e099e3-4c96-4422-a8c4-3a6bff21bcfa,
  abstract     = {<p>Background and purpose: Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical occurrence of impulse control behaviours on longer acting/transdermal DA therapy across age ranges are lacking. The aim of this study was to assess the occurrence of ICDs in PD patients across several European centres treated with short- or long-acting [ropinirole (ROP); pramipexole (PPX)] and transdermal [rotigotine skin patch (RTG)] DAs, based on clinical survey as part of routine clinical care. Methods: A survey based on medical records and clinical interviews of patients initiating or initiated on DA treatment (both short- and long-acting, and transdermal) across a broad range of disease stages and age groups was performed. Results: Four hundred and twenty-five cases were included [mean age 68.3 years (range 37-90), mean duration of disease 7.5 years (range 0-37)]. ICD frequencies (as assessed by clinical interview) were significantly lower with RTG (4.9%; P &lt;0.05) compared with any other assessed DAs except for prolonged release PPX (PPX-PR). The rate of ICDs for PPX-PR (6.6%) was significantly lower than for immediate release PPX (PPX-IR) (19.0%; P &lt;0.05). Discontinuation rates of DA therapy due to ICDs were low. Conclusion: Our data suggest a relatively low rate of ICDs with long-acting or transdermal DAs, however these preliminary observational data need to be confirmed with prospective studies controlling for possible confounding factors.</p>},
  author       = {Rizos, A. and Sauerbier, A. and Antonini, A. and Weintraub, D. and Martinez-Martin, P. and Kessel, B. and Henriksen, T. and Falup-Pecurariu, C. and Silverdale, M. and Durner, G. and Røkenes Karlsen, K. and Grilo, M. and Odin, P. and Chaudhuri, K. Ray},
  issn         = {1351-5101},
  keyword      = {Dopamine agonists,Dopamine dysregulation syndrome,Impulse control behaviours/disorders,Parkinson's disease},
  language     = {eng},
  month        = {05},
  number       = {8},
  pages        = {61--1255},
  publisher    = {ARRAY(0xa55ea38)},
  series       = {European Journal of Neurology},
  title        = {A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists},
  url          = {http://dx.doi.org/10.1111/ene.13034},
  volume       = {23},
  year         = {2016},
}